In T-ALL, PLK1 seems to be the dominant isoform, and an inhibitor targeting PLK1 displayed considerable inhibitory potential against cultured cell lines, ex-vivo treatments of PDXs, and a mouse xenograft model. Here, PLK1 is linked to acute lymphoblastic leukemia.